Blog hero background graphic

Blog

First-time launch data investments: How do you balance flexibility, cost, and commitment in data decisions?

First-time launch data investments: Explore key market pressures, common pitfalls, and practical roadmap strategies to guide smarter data...

First-time launch data investments: How do you balance flexibility, cost, and commitment in data decisions?featured image

Buy vs build vs hybrid : What’s the right call for your data infrastructure in first-time launches?

First-time launch sequencing: How do you launch a product and a company at the same time?

Obesity pill launches show Lilly, Novo plugging operational gaps

Hybrid Liaisons, Sales Pods, and AI: Reimagining the Pharma Rep

First-time launch data decisions: What to buy, what to rent, and when to do it

Patients are reshaping the health information journey

J&J’s new psoriasis pill to challenge older biologics

Could an FDA official’s exit spell regulatory relief for biotech?

The Beghou Biopharma Review

Rep, regulatory shifts quicken pharma’s commercial evolution

The Beghou Biopharma Review

Closing out 2025: AI's big leap and the search for organizational harmony

The Beghou Biopharma Review

Dealing with dual demands: Tariffs, price caps create competing pressures for pharma marketers

The Beghou Biopharma Review

From trade tensions to therapy pivots: What’s shaping pharma this summer

The Beghou Biopharma Review

Launch radar: What 2026’s drug launches signal to commercial leaders; 4 questions for AbbVie’s Brent Hasko

Patient-centric commercialization in practice: Lessons from consumer-oriented and specialty Rx brands

Building a vendor strategy: Protecting commercial plans from supplier-driven data risk